North America Autoimmune Disease Diagnostics Market Size, Share & Trends Analysis Report By Product Type (Instruments, Assay Kits & Consumables), By Disease Type (Systemic Autoimmune Diseases), By Technology (Immunoassays, Indirect Immunofluorescence, Multiplex Assays, Molecular Diagnostics, Point-of-Care Testing, Other Technology), By End User (Hospitals & Clinics, Clinical Laboratories, Academic & Research Institutes, Other End Users) and By Country (US, Canada) Forecasts, 2026-2034

North America Autoimmune Disease Diagnostics Market Size

The North America autoimmune disease diagnostics market size was valued at USD 2.68 billion in 2025 and is projected to grow from USD 2.90 billion in 2026 to reach USD 5.45 billion million by 2034, growing at a CAGR of 8.2% during the forecast period 2026-2034.

Autoimmune illnesses are also characterized by the activation of self-reactive T cells, the production of autoantibodies, and inflammation. Immune cells may recognize foreign substances such as bacteria and viruses and send out fighter cells to combat them. The immune system is forced to combat itself in autoimmune illnesses.

But in certain cases, the immune system misidentifies parts of your body, such as your joints or skin, as an alien in an autoimmune disease. Autoantibodies are proteins released by the body that assault healthy cells. Some autoimmune disorders are limited to a single organ. The pancreas is harmed by type 1 diabetes. Systemic lupus erythematosus (SLE), for example, affects the entire body. These are non-communicable conditions in which the immune system loses its natural balance. This organism is in charge of causing an abnormal response in its tissue cells.

North America Autoimmune Disease Diagnostics Market Segmentation Analysis

By Product Type

The North America Autoimmune Disease Diagnostics Market is segmented into Instruments and Assay Kits & Consumables. Instruments include automated analyzers, immunoassay systems, fluorescence-based platforms, and other laboratory equipment used to detect and analyze autoimmune biomarkers, while assay kits and consumables include reagents, antibodies, controls, calibrators, test kits, and other materials required for autoimmune diagnostic testing. Instruments support automation, standardized workflows, and high-throughput testing, whereas assay kits and consumables are essential for routine and specialized diagnostic procedures. Increasing demand for accurate and efficient autoimmune disease detection is supporting adoption across both product categories.

Growing awareness of autoimmune disorders, increasing diagnostic testing volumes, technological advancements, and expansion of clinical laboratory infrastructure are driving demand for autoimmune diagnostic products across North America. Instruments are benefiting from the increasing adoption of automated and integrated laboratory platforms that improve testing efficiency and consistency, while assay kits and consumables benefit from recurring demand associated with routine testing and disease monitoring. Growing emphasis on early diagnosis, personalized treatment, and improved clinical decision-making is expected to create further opportunities for manufacturers of diagnostic instruments, assay kits, and consumables.

Request Customizationto receive a tailored report.

By Disease Type

The North America Autoimmune Disease Diagnostics Market is segmented by disease type into Systemic Autoimmune Diseases. Systemic autoimmune diseases occur when immune system dysfunction affects multiple organs or tissues and include conditions such as systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis, Sjögren's syndrome, and other systemic autoimmune disorders. Diagnosis commonly involves clinical evaluation combined with laboratory testing for autoantibodies and other disease-related biomarkers. Increasing demand for accurate laboratory confirmation and disease-specific testing is supporting the use of specialized diagnostic technologies for systemic autoimmune conditions.

The growing prevalence and clinical burden of systemic autoimmune diseases across North America are increasing demand for early and accurate diagnosis. Aging populations, rising awareness of autoimmune conditions, improved access to healthcare, and greater emphasis on disease monitoring are encouraging healthcare providers to use advanced diagnostic tests. Continued development of biomarker-based assays, automated laboratory platforms, and more sensitive testing methods is expected to strengthen diagnostic capabilities and support the expansion of systemic autoimmune disease testing across the region.

By Technology

The North America Autoimmune Disease Diagnostics Market is segmented into Immunoassays, Indirect Immunofluorescence, Multiplex Assays, Molecular Diagnostics, Point-of-Care Testing, and Other Technology. Immunoassays are widely used to detect autoantibodies and other biomarkers associated with autoimmune diseases, while indirect immunofluorescence is used for antibody screening and identification of characteristic fluorescence patterns. Multiplex assays enable simultaneous testing of multiple biomarkers, molecular diagnostics provide nucleic-acid-based testing capabilities for selected applications, and point-of-care testing enables diagnostic assessment closer to the patient. Other technologies include emerging and specialized diagnostic approaches used for autoimmune disease detection and monitoring.

Increasing demand for rapid, accurate, sensitive, and comprehensive diagnostic testing is supporting technology development across North America. Immunoassays continue to benefit from broad clinical adoption and laboratory automation, while multiplex technologies are gaining importance because they can evaluate multiple biomarkers within a single testing workflow. Molecular diagnostics and point-of-care testing are also creating opportunities by improving specialized testing capabilities and accessibility. Increasing investment in precision medicine, biomarker research, laboratory automation, and advanced diagnostic platforms is expected to encourage adoption of innovative technologies in autoimmune disease diagnostics.

By End User

The North America Autoimmune Disease Diagnostics Market is segmented into Hospitals & Clinics, Clinical Laboratories, Academic & Research Institutes, and Other End Users. Hospitals and clinics use autoimmune diagnostic tests for disease evaluation, confirmation, treatment planning, and patient monitoring, while clinical laboratories perform high volumes of routine and specialized autoimmune testing for healthcare providers. Academic and research institutes use these technologies for biomarker discovery, disease research, clinical studies, and development of new diagnostic methods. Other end users include specialized healthcare organizations and research facilities requiring autoimmune diagnostic capabilities.

Clinical laboratories represent a major end-user category because of their role in centralized and specialized testing, while hospitals and clinics continue to generate demand through increasing diagnosis and monitoring of autoimmune disorders. Academic and research institutes contribute to market development through research into disease mechanisms, biomarkers, diagnostic technologies, and personalized treatment strategies. Increasing healthcare expenditure, expansion of laboratory infrastructure, growing diagnostic awareness, and demand for earlier and more accurate autoimmune disease detection are expected to support adoption across hospitals and clinics, clinical laboratories, research institutes, and other end-user settings.

Speak to an Analystto discuss market opportunities.

List of Key and Emerging Players in North America Autoimmune Disease Diagnostics Market